The Co-Expression of Melanoma-Antigen Family a Proteins and New York Esophageal Squamous Cell Carcinoma-1 in Breast Cancer: A Pilot Study

Figures & data

Table 1 Clinical Data of the 122 Breast Cancer Patients

Clinical Parameters	Cases (n)	Percent (%)
Age (years)
<55	66	54.10
≥55	56	45.90
Clinical stage
I	20	16.39
II	76	62.30
III	26	21.31
Histological grade
I	16	13.11
II	74	60.66
III	32	26.23
Size of tumor (cm)
≤2	14	11.48
>2 or ≤5	24	19.67
>5	84	68.85
Metastatic state of lymph node
No	62	50.82
Yes	60	49.18
Estrogen receptor status
–	44	36.07
+	78	63.93
Progesterone receptor status
–	46	37.70
+	76	62.30
P53 status
–	72	59.02
+	50	40.98
Human epidermal growth factor receptor 2 status
–	70	57.38
+	52	42.62
Vascular endothelial growth factor status
–	12	9.84
+	110	90.16

Figure 1 Positive expression of MAGE-A/NY-ESO-1 in breast cancer tissues.

Figure 2 (A and B) Chi-square or Fisher’s exact test analysis of associations between expression of MAGE-A/NY-ESO-1 and clinical diagnostic or experimental biomarkers.

Abbreviations: ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor receptor 2; LN, lymph node; MAGE-A, melanoma-antigen family A protein; NY-ESO-1, New York esophageal squamous cell carcinoma-1.

Figure 3 Kaplan–Meier survival analysis of the whole follow-up cohort.